PCOS Associated With Greater Risk of Asthma

MedicalResearch.com Interview with:
Dr Anju Joham (MBBS (Hons), FRACP, PhD)
Endocrinologist, Monash Health
Post doctoral Research Fellow
Monash Centre for Health Research and Implementation – MCHRI
School of Public Health and Preventive Medicine
Monash University – in partnership with Monash Healtj

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Johan: Polycystic Ovary Syndrome (PCOS) is a common condition affecting reproductive-aged women. Recent research suggests that asthma may be more commonly seen in women with PCOS; however, there are very limited studies that have examined this relationship. It will be helpful to understand if there is a relationship with PCOS and asthma.

Women were randomly selected from the national health insurance database (Medicare) in Australia. Data was available for 8612 women. We found that in women aged 28 to 33 years, PCOS prevalence was 5.8% (95% CI: 5.3%-6.4%). The prevalence of asthma was 15.2% in women reporting PCOS and 10.6% in women not reporting PCOS respectively. PCOS was associated with 34% increased odds of asthma after adjusting for weight. In addition, weight in the overweight and obese range were associated with increased odds of asthma.

Continue reading

Thyroiditis in Patients Receiving Immune Checkpoint Blockade Therapies Characterized

MedicalResearch.com Interview with:

Le Min, MD,PhD Brigham and Women's Hospital, Endocrinology Division

Dr. Le Min

Le Min, MD,PhD
Brigham and Women’s Hospital, Endocrinology Division

MedicalResearch.com: What is the background for this study?

Dr. Min: As you know, immune checkpoint blockade therapies by anti-CTLA4 and Anti-PD1 have shown promising and durable anti-cancer effects on several advanced malignancies. Interestingly, endocrine disorders are among the most common adverse effects associated with immune checkpoint blockade therapies. More interestingly, it appears that hypophysitis, the inflammation of the pituitary is commonly related to anti-CTLA4 therapy while thyroid disorders are more commonly seen in anti-PD1 monotherapy and the combined therapy with anti-PD1 and anti-CTLA4.

Anti-CTLA4-related hypophysitis has been well characterized but there is no study to characterize the thyroid disorders associated with anti-PD1 monotherapy and the combined therapy with anti-PD1 and anti-CTLA4. As an endocrinologist, I have been taking care of a population of such patients who received either monotherapy with anti-PD1 or combined therapy with anti-PD1 and anti-CTLA4 and developed thyroid disorders.

Continue reading